GlobeStar Therapeutics Corporation
GSTC · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.02 | -0.00 | 0.05 |
| FCF Yield | -13.82% | -14.06% | -5.26% | -11.91% |
| EV / EBITDA | 275.91 | -1.85 | -1.58 | -6.96 |
| Quality | ||||
| ROIC | 174.56% | 107.70% | 1,467.51% | 60.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -48,837.66% |
| Cash Conversion Ratio | 0.11 | 0.22 | 0.08 | 0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -55.77% |
| Free Cash Flow Growth | 37.08% | 56.47% | -211.05% | 7.16% |
| Safety | ||||
| Net Debt / EBITDA | 54.43 | -0.01 | -0.01 | -0.24 |
| Interest Coverage | -20.35 | -17.98 | -31.63 | -1.28 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 15.62 |
| Cash Conversion Cycle | 0.00 | 0.00 | -33,712.26 | -1,269.44 |